Pediatric Weight Gain From Atypical Antipsychotics Returns To FDA Advisory Cmte.
This article was originally published in The Pink Sheet Daily
Executive Summary
Panel urged label changes two years ago, but the products still do not include uniform information in their warning sections. FDA is asking its Pediatric Advisory Committee to review the pediatric safety of Bristol/Otsuka's Abilify, along with an AHRQ report on weight gain associated with the class of products.
You may also be interested in...
Australia's CSL Slapped With U.S. FDA Warning Letter Over Flu Vaccine
U.S. FDA's Center for Biologics Evaluation and Research slapped CSL Biotherapies with a warning letter June 15 for significant objectionable conditions related to current good manufacturing practices at its Victoria, Australia, manufacturing plant
Atypical Antipsychotics To Add Warning About Metabolic Effects In Kids
FDA likely will move metabolic information to the warning section in labeling for all atypical antipsychotics, according to Division of Psychiatry Products Director Thomas Laughren
Cancer-Genomics Firm Quanticel Debuts With Close Ties To Celgene, And An Exit In Mind
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.